Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

eosinophilic

- PMLiVE

FDA panel backs Novo Nordisk’s liraglutide for obesity

Committee says diabetes drug could be used to reduce weight

- PMLiVE

Pre-chemotherapy indication for Xtandi in prostate cancer

Astellas drug set to compete with J&J’s Zytiga

- PMLiVE

Second time lucky for Takeda’s obesity drug

FDA approves Contrave three years after initial rejection

- PMLiVE

FDA panel votes against Actavis hypertension combo

Places a question mark over the combination of Bystolic and Diovan

- PMLiVE

Liraglutide seems effective in obesity, says FDA reviewer

Novo Nordisk drug is already successful diabetes treatment

- PMLiVE

Questions raised about affordability of asthma antibodies

Positive data on GSK and Teva anti-IL-5 candidates at ERS congress highlights cost concerns

- PMLiVE

Boehringer’s Spiriva cleared for asthma in EU

Drug approved as a treatment for adults with severe asthma

- PMLiVE

Teva supports launch of MS help website

Pow Health aims to help patients in Ireland with long term illnesses

- PMLiVE

Merck brings first PD-1 inhibitor to US market

FDA approves Keytruda for advanced melanoma

- PMLiVE

Drug regulators collaborate to tackle Ebola outbreak

EMA and FDA team up with global partners to accelerate access to medicines

- PMLiVE

Amgen submits melanoma and cholesterol drugs to EMA

Regulator will assess talimogene laherparepvec and evolocumab

- PMLiVE

Teva stakes its claim to the asthma antibody market

Plans to file reslizumab early next year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links